JPRN-jRCT2080223566已完成3 期
A long-term Study of DE-114A Ophthalmic Solution in Patients with Allergic Conjunctivitis - Phase 3
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 121
研究概览
简要总结
DE-114A ophthalmic solution was instilled twice a day (morning and evening) for 8 weeks in subjects with allergic conjunctivitis. As a result, the safety and efficacy of long-term administration were confirmed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Provided signed, written informed consent.
- •Has a positive result from a Type I allergy test.
排除标准
- •Eye disease other than allergic conjunctivitis is present and requires treatment.
- •Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.
研究者
相似试验
已完成
3 期
Phase3 Study of DE-114A Ophthalmic Solution in Patients With Allergic ConjunctivitisAllergic ConjunctivitisJPRN-jRCT2080223524SANTEN PHARMACEUTICAL CO., LTD.68
已完成
3 期
A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic ConjunctivitisAllergic ConjunctivitisNCT01363713Santen Pharmaceutical Co., Ltd.130
已完成
3 期
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE StudyOpen Angle Glaucoma or Ocular HypertensionNCT02822729Santen Pharmaceutical Co., Ltd.125
已完成
3 期
Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract SurgeryCataract SurgeryNCT02573610Santen Pharmaceutical Co., Ltd.576
已完成
1 期
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye DiseaseDry Eye DiseaseNCT03216096Santen Pharmaceutical Co., Ltd.20